MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma

Jeffery Goldstein, Rajen Goyal, Joseph T. Roland, Lan L. Gellert, Peter E. Clark, Omar Hameed*, Giovanna A. Giannico

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Objectives: We compared the utility of membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2) and α-methylacyl CoA (AMACR) by immunohistochemistry in diagnosing prostatic adenocarcinoma. Methods: Seventy-eight radical prostatectomies were used to construct three tissue microarrays with 512 cores, including benign prostatic tissue, benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia (HGPIN), and adenocarcinoma. AMACR and MAGI-2 immunohistochemistry were evaluated by visual and image analysis. Results: MAGI-2 and AMACR were significantly higher in adenocarcinoma and HGPIN compared with benign tissue. At H-score cutoffs of 300 and 200, MAGI-2 was more accurate in distinguishing benign from malignant glands than AMACR. Areas under the curve by image and visual analysis were 0.846 and 0.818 for MAGI-2 and 0.937 and 0.924 for AMACR, respectively. The accuracy of MAGI-2 in distinguishing benign from malignant glands on the same core was higher (95% vs 88%). Conclusions: MAGI-2 could represent a useful adjunct for diagnosis of prostatic adenocarcinoma, especially when AMACR is not discriminatory.

Original languageEnglish (US)
Pages (from-to)294-302
Number of pages9
JournalAmerican journal of clinical pathology
Volume146
Issue number3
DOIs
StatePublished - Sep 1 2016

Keywords

  • AMACR
  • MAGI-2
  • Prostate cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma'. Together they form a unique fingerprint.

  • Cite this

    Goldstein, J., Goyal, R., Roland, J. T., Gellert, L. L., Clark, P. E., Hameed, O., & Giannico, G. A. (2016). MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma. American journal of clinical pathology, 146(3), 294-302. https://doi.org/10.1093/ajcp/aqw111